News

The company announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit.

Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis.

The HPTN 052 clinical trial, an international HIV prevention trial, has been chosen by the journal Science as the 2011 Breakthrough of the Year.

The completed program has resulted in the application of a new, advanced antibody assay technique, a label-free optical microarray detection platform, for high-throughput measurements of antibody-antigen interactions.

Phase II study of reovirus with paclitaxel and carboplatin in patients with metastatic NSCLC.

The findings have important implications for studying the conservation of the genetic diversity and origins of sweet potato.

The Company plans to use funds from any draw down of the loan to support continued development of its product pipeline and for general corporate purposes.

$2.6 Million Payment From AstraZeneca Due to Dynavax as the companies announce their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies.

The report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

Dr. Gong brings more than 12 years of experience that includes both R&D and clinical expertise in the development of diagnostics. In her new role, she will be responsible for overseeing the In Vitro Diagnostics (IVD) business within the company.